Skip to content
Screener

Zevra Therapeutics, Inc. ZVRA Business Segments — Depreciation and amortization expense

Similar metrics at other companies

Stem logo
STEMReportable Segment — Depreciation and amortization expense
$3.34M-21.3%
Rimini Street, Inc. logo
RMNIReportable Segment — Depreciation and amortization expense
$995K+7.0%
Tarsus Pharmaceuticals, Inc. logo
TARSReportable Segment — Depreciation and amortization expense
-$1M-121%
RXO logo
RXOReportable Segment — Depreciation and amortization expense
$26M-13.3%
Option Care Health, Inc. logo
OPCHReportable Segment — Depreciation and amortization expense
$17.45M+7.5%
Archer Aviation logo
ACHRReportable Segment — Depreciation and amortization expense
$10.1M+110%

Other financials

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$686.48M+7.3%
Enterprise value$542.65M-17.1%
P/E11.8×-230×
P/S-5.3×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity-0.5×
Current ratio5.2×-2.7×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001434647-26-000068
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Other segment items:
Impairment of intangible assets58,71058,710
Income tax expense4,0422,19910,9573,381
Interest income(1,477)(2,257)(3,661)(2,975)
Depreciation and amortization expense3161,6517323,300
Interest expense2,0091,7113,978
Other income, net (a)6,985(135,353)(26,718)(138,738)
Segment net income$8,752$74,707$46,642$71,608

ITEM 1.FINANCIAL STATEMENTS

FAQ

What is Zevra Therapeutics, Inc.'s business segments — depreciation and amortization expense?
Zevra Therapeutics, Inc. (ZVRA) reported business segments — depreciation and amortization expense of $316K in Q2 2026.
How has Zevra Therapeutics, Inc.'s business segments — depreciation and amortization expense changed year-over-year?
Zevra Therapeutics, Inc.'s business segments — depreciation and amortization expense decreased by 80.9% year-over-year, from $1.65M to $316K.
What does business segments — depreciation and amortization expense mean?
Represents the non-cash allocation of the cost of tangible and intangible assets over their useful lives within the segment. This metric is critical for understanding the capital intensity of the segment and its underlying asset base.

Ask your AI about Zevra Therapeutics, Inc.'s business segments — depreciation and amortization expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude